"我们初步考虑以普陀区为切入点，深度对接上海全域，重点系统谋划'产业供需清单''科创需求清 单''场景应用清单'三张清单，通过推动扬州专业园区与上海特色园区建立'伙伴园区'，深度融入上海大 都市圈。"扬州市发展改革委主任陆安亚介绍，扬州已在上海设立4家域外创新中心，发展改革委还将牵 头组织市属国企打造扬州与上海合作的"沪扬产业协同创新中心"，推进"三张清单"对接工作。 数据显示，今年1—10月，扬州共招引亿元以上项目1306个，其中投资来源地为上海、苏州、无锡、南 京的项目共177个、占比13.6%。"加入沿沪宁产业创新带，为扬州加快推进产业科创名城建设带来重要 契机。"扬州市委主要领导表示，扬州将积极主动融入上海大都市圈建设，合力打造更多具有标志性、 引领性创新成果，为深入推进长三角一体化发展作出更大贡献。周晶 张江立表示，几年前公司刚落户扬州时，"从奠基到投产仅用一年时间"的"扬州速度"令他感动，毫不犹 豫将总部在此扎根。如今企业已经拥有丰富的产品研发管线，研发团队今年刚刚攻克消化道多癌早筛难 题。"从上海来扬州创业，让我看到更多可能性。"张江立说，公司前不久入选2025年江苏独角兽企业， 更多资源和创新 ...

Core Viewpoint - The new share issuance results of Bai'ao Saitou indicate strong demand from offline investors, while online investors showed a low abandonment rate, reflecting overall positive market sentiment towards the company’s stock [1][2][3] Summary by Category Share Issuance Results - The total number of shares issued by the company was 47.50 million, with an issuance price of 26.68 yuan per share [3] - Online investors subscribed for 11.42 million shares, amounting to 304.68 million yuan, while offline investors subscribed for 27.15 million shares, totaling 724.27 million yuan [2][3] - The abandonment rate for online subscriptions was 0.36%, with 4.12 thousand shares abandoned, amounting to 109.98 thousand yuan [1][2] Subscription Details - The final online issuance volume accounted for 24.13% of the total issuance, with a final online winning rate of 0.028% [3] - Offline investors fully subscribed, and the number of shares abandoned by online investors was fully underwritten by the lead underwriter, representing 0.09% of the total issuance [1][3] Recent Trends in New Share Issuance - In the past month, notable companies with high online subscription abandonment included C China Uranium, Nanfang Digital, and Hai'an Group, with abandonment rates of 0.71%, 0.40%, and 0.38% respectively [3] - Bai'ao Saitou's abandonment rate of 0.36% places it among the companies with lower abandonment rates in recent new share issuances [3]

12月3日，港股指数低开低走，截止午盘，恒生指数跌0.97%报25842.77点，恒生科技指数跌1.3%报 5550.92点，国企指数跌1.26%报9067.4点，红筹指数跌0.64%报4250.67点。 盘面上，科技股集体弱势拖累大市走低，阿里巴巴跌1.97%，腾讯控股跌1.05%，京东集团跌0.26%，小 米集团跌0.79%，网易跌3.3%，美团跌0.67%，快手跌1.67%，哔哩哔哩跌2.7%；有色金属股活跃，中国 铝业涨超5%；汽车股走弱，小鹏汽车跌超3%；生物医药板块普跌，药明合联跌超3%；今日两只新股上 市，乐摩科技涨超56%，金岩高岭新材涨超1%。 企业新闻 中国东方集团(00581.HK)：斥资约5200万元收购江苏神通375.35万股股份。 黑芝麻智能(02533.HK)：拟斥资约4亿-5.5亿元获取珠海亿智电子科技有限公司多数股权，预期收购事项 将于2026年第一季度完成。 国富氢能(02582.HK)：完成配售485.8万股，净筹约1.97亿港元，约60%用于中国及海外氢能项目的融资 投资及合作。 中国秦发(00866.HK)：非全资附属SDE与浙江能源亚太订立供煤协议，将提供15万公吨 ...

（原标题：港股收评：恒指涨0.24%，银河娱乐涨近3%领跑博彩股，生物医药股下跌） 12月2日，港股三大指数早盘高开盘中回落曾集体转跌，午后又再度回升，总体波动不大，市场情绪平稳。恒生指数、国企指数分别上涨0.24%及 0.11%，恒生科技指数则下跌0.37%。 盘面上，大型科技股涨跌不一，美团跌3%，阿里巴巴、小米小幅上涨；工程机械出海大趋势明显，重型机械股集体走强，龙头三一重工、中联重 科涨幅靠前；摩通看好澳门博彩股明年趋势，濠赌股全天维持上涨行情；煤炭股、保险股、石油股、内房股、苹果概念股多数上涨。另一方面， 11月汽车股交付出炉，汽车股走势出现两极分化，广汽集团大涨超7%，"蔚小理"全天表现低迷；药品股、影视娱乐股、半导体芯片股多数下跌。 具体来看： 大型科技股涨跌不一，阿里巴巴、小米小幅上涨，美团跌3%。 重型机械股集体走强，龙头三一重工涨5.62%，中联重科涨1.78%，中国龙工涨1.35%。 消息面上，中国工程机械工业协会数据显示，10月销售各类挖掘机18096台，同比增长7.77%，其中国内销量8468台，同比增长2.44%；出口销量 9628台，同比增长12.9%。中信建投指出，在当前时间点 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 白内障 作为全球排名首位致盲性眼病，患者数量超过 9500 万。随着糖尿病发病率攀升， 糖尿病性白内障 （DC） 的防治压力日益加剧。临床上，糖尿病性白内 障患者手术并发症风险比普通患者高约 30%，但其术前精准诊断却面临两大难题： 诊断滞后 ：依赖患者自述病史或单次血糖检测，易漏诊； 采样困难 ：传统分 子诊断需采集眼内房水等侵入性样本，无法用于术前筛查。 眼泪 是唯一可直接获取的眼部非侵入性体液，但因其微量特性 （单次采集仅微升级别） ，一直难以实现高效代谢分析。 近日， 华东师范大学 万晶晶 教授团队 联合上海交通大学医学院附属第九人民医院 范先群 院士、 苏蕴 副研究员 、 郭涛 主任医师，在 Nature 子刊 Nature Communications 上发表了题为： A mass spectrometry-based strategy allows signature metabolite identification in tear fluid from people with diabetic cataracts 的研究论文。 这项研究颠覆了传统眼科诊 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-085 登录新浪财经APP 搜索【信披】查看更多考评等级 北京热景生物技术股份有限公司 关于与关联方共同投资尧景基因 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热景生物"）、林长青、北京尧景企 业管理中心（有限合伙）（以下简称"尧景合伙"）拟共同对北京尧景基因技术有限公司（以下简称"尧 景基因"）进行增资，增资方案为热景生物出资2,400万元，林长青出资5,000万元，尧景合伙出资600万 元，合计出资8,000万元，按照2元/注册资本的价格进行增资。本次增资完成后，尧景基因注册资本由 11,000万元变更为15,000万元，公司持有尧景基因的股权比例由40.91%变更为38.00%。 ● 本次增资方林长青为公司控股股东、实际控制人、董事长兼总经理；增资方北京尧景企业管理中心 （有限合伙）为林长青担任执行事务合伙人、公司董事柳晓利、许立达及公司副总经理兼董事 ...

Major Events - 加科思-B (01167) published data on KRAS G12C and SHP2 combination therapy in The Lancet Respiratory Medicine [1] - 励晶太平洋 (00575) announced strategic entry into the US market by Deep Longevity in Q1 2026 [1] - 和誉-B (02256) received FDA approval for IND application of oral small molecule KRAS G12D inhibitor ABSK141 [1] - 中国生物制药 (01177) completed the first patient enrollment in Phase I clinical trial for its self-developed innovative drug TRD208 in China [1] - 天图投资 (01973) plans to sell 45.22% stake in 优诺中国 for HKD 814 million [1] - 万国黄金集团 (03939) donated HKD 7 million to support victims of the Hong Kong fire [1] - 和谐汽车 (03836) donated HKD 5 million for fire rescue efforts in Hong Kong [1] - 博雅互动 (00434) donated HKD 1 million for post-disaster reconstruction in Hong Kong [1] - 粤港湾控股 (01396) launched a self-developed quantum computing cloud service scheduling platform [1] - 中基长寿科学 (00767) plans to acquire 25% stake in 综合细胞库有限公司 for HKD 300 million [1] - 众安集团 (00672) plans to place approximately 7.15% of its shares at a premium of about 1.96%, raising approximately HKD 74.96 million [1] - 江苏宏信 (02625) plans to increase investment in 海科宏信 by HKD 53.21 million [1] Share Buybacks/Reductions - 百融云-W (06608) plans to repurchase up to HKD 450 million of Class B shares [2] - 锦欣生殖 (01951) intends to repurchase shares for no less than HKD 100 million [2] - 小米集团-W (01810) repurchased 10 million shares for HKD 402 million on December 1 [2] - 腾讯控股 (00700) repurchased 102.9 million shares for HKD 636 million on December 1 [2] - 美的集团 (00300) repurchased 125.48 million A shares for HKD 9.9971 million on December 1 [2] - 中远海控 (01919) repurchased 94.5 million shares for HKD 12.76 million on December 1 [2] - 美丽田园医疗健康 (02373) saw non-executive director 李方雨 increase holdings by 41,500 shares [2] Operating Performance - 比亚迪股份 (01211) reported approximately 4.182 million electric vehicle sales in the first 11 months, a year-on-year increase of 11.3% [2] - 吉利汽车 (00175) achieved total vehicle sales of 2.78775 million units in the first 11 months, a year-on-year increase of 42% [2] - 长城汽车 (02333) reported approximately 1.19965 million vehicle sales in the first 11 months, a year-on-year increase of 9.26% [2] - 赛力斯 (09927) recorded total vehicle sales of 58,100 units in November, a year-on-year increase of 36.34% [2] - 蔚来-SW (09866) delivered approximately 36,300 vehicles in November, a year-on-year increase of 76.3% [2] - 小鹏汽车-W (09868) delivered 36,728 smart electric vehicles in November, a year-on-year increase of 19% [2] - 奇瑞汽车 (09973) reported total sales of 255,800 vehicles across five brands in November, a year-on-year decrease of approximately 2% [3] - 理想汽车-W (02015) delivered 33,181 new vehicles in November [3]

Group 1 - The core viewpoint of the news is the establishment of the "CITIC Construction Investment - Waigaoqiao Group Holding Real Estate Asset Support Special Plan," which is the first industrial plant-based asset-backed security (ABS) in the inter-institutional REITs market in China, with a total issuance scale of 1.83 billion yuan [1] - This project expands the asset range of inter-institutional REITs and creates a new equity financing channel for local state-owned enterprises, demonstrating a significant effect [1] - The underlying assets consist of four standard factory projects held by Waigaoqiao Group, located in the Waigaoqiao Free Trade Zone, with a total construction area of approximately 190,600 square meters and an average occupancy rate of 93.16% [1] Group 2 - Inter-institutional REITs are positioned as equity-type listed products and are an important part of building a multi-tiered REITs market, serving as an innovative tool for revitalizing existing assets and expanding effective investment [2] - Since the launch of the first inter-institutional REITs in 2023, the Shanghai Stock Exchange has successfully issued 20 projects with a total issuance scale exceeding 45 billion yuan, with nearly 1,200 billion yuan in total application scale [2] - The Shanghai Stock Exchange is committed to developing the inter-institutional REITs market while ensuring safety and focusing on the authenticity and reliability of underlying assets, as well as accurate and complete information disclosure [3] Group 3 - The Shanghai Stock Exchange aims to stimulate market vitality and ensure the market's sustainable and healthy development by respecting market rules and enhancing the market mechanism [3] - Future efforts will focus on organizing and building the inter-institutional REITs market ecosystem, promoting project implementation, and improving relevant mechanisms and supporting rules [3]

（原标题：优瑞科生物科技CEO刘诚：让世界读懂中国对全球新药研发的贡献） 美国优瑞科生物科技公司创始人兼CEO刘诚在接受南方财经全媒体集团记者采访时，强调中国举办更多 科学及新药研发领域国际会议与专题研讨会的重要性。他认为，这类专业交流不仅能够帮助全球更全 面、更深入地了解中国在相关领域的最新进展，也能让国际社会充分理解与认可中国科学家在全球药物 研发方面的贡献。 策划：赵海建 监制：黄燕淑 南方财经 21世纪经济报道记者 黄子豪 庄欢 郑全怡 广州报道 11月30日至12月1日，2025年"读懂中国"国际会议在广州举行。大会以"新布局、新发展、新选择——中 国式现代化与全球治理新格局"为主题，汇聚全球知名政治家、学者、业界领袖及国际组织代表等重量 级嘉宾，聚焦"十五五"规划及其世界意义，就中国式现代化创新发展的新布局及其为世界现代化提供的 新机遇，携手践行全球治理倡议等相关议题展开研讨。 海外运营监制: 黄燕淑 海外运营内容统筹: 黄子豪 海外运营编辑：庄欢 吴婉婕 龙李华 郑全怡 出品：南方财经全媒体集团 内容：黄子豪 庄欢 郑全怡 ...

Core Viewpoint - SystImmune has received a milestone payment of $250 million from BMS as part of a collaboration agreement for the development and commercialization of the BL-B01D1 project, a dual-target ADC with significant clinical value and market potential [1][3]. Group 1 - SystImmune is focused on addressing unmet clinical needs in the field of biomedicine, particularly in tumor macromolecule therapies, and aims to establish global commercialization capabilities by 2029 [1]. - The collaboration agreement includes an upfront payment of $800 million from BMS, with potential additional payments reaching up to $5 billion based on specific milestones, and a total potential deal value of up to $8.4 billion [2]. - As of March 7, 2024, SystImmune has received an irrevocable and non-deductible upfront payment of $800 million from BMS [2]. Group 2 - SystImmune will be exclusively responsible for the development and commercialization of BL-B01D1 in mainland China, while BMS will handle the development and commercialization in other global regions [2]. - The agreement stipulates that SystImmune is eligible for additional payments of up to $250 million based on recent or contingent milestones, and up to $7.1 billion upon achieving specific development, registration, and sales milestones [3].